Answers are grounded in this paper and cite their sources.
A “relay drug delivery” system based on two distinct modules, which is composed of a signal transmission nanocarrier A (NCA) that can specifically induce tumor blood vessel inflammation generation and an execution biomimetic nanocarrier B (NCB) that can accumulate at the tumor site by receiving the broadcasting signals generated by NCA, is developed for amplifying active tumor targeting signal and enhancing antitumor therapy.
No takes yet. Share an insight, caveat, or question.
Hu et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: